These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3671965)

  • 1. [Neuropsychic side effects of bromocriptine in Parkinson's disease].
    Simonetta M; Schmitt L; Montastruc JL; Rascol A
    Rev Neurol (Paris); 1987; 143(8-9):608-11. PubMed ID: 3671965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients.
    Serby M; Angrist B; Lieberman A
    Adv Biochem Psychopharmacol; 1980; 23():287-92. PubMed ID: 6104908
    [No Abstract]   [Full Text] [Related]  

  • 4. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

  • 5. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease.
    Stern GM; Lees AJ
    Adv Neurol; 1983; 37():17-21. PubMed ID: 6858771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine mesylate in Parkinson's disease.
    Lieberman A; Kupersmith M; Neophytides A; Casson I; Durso R; Foo SH; Khayali M; Tartaro T
    N Y State J Med; 1979 Oct; 79(11):1689-92. PubMed ID: 290866
    [No Abstract]   [Full Text] [Related]  

  • 9. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromocriptine and lisuride in Parkinson's disease.
    Caraceni T; Giovannini P; Parati E; Scigliano G; Grassi MP; Carella F
    Adv Neurol; 1984; 40():531-5. PubMed ID: 6695632
    [No Abstract]   [Full Text] [Related]  

  • 12. Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease.
    Serby M; Angrist B; Lieberman A
    Am J Psychiatry; 1978 Oct; 135(10):1227-9. PubMed ID: 29497
    [No Abstract]   [Full Text] [Related]  

  • 13. Mental disorders in Parkinson's disease after treatment with L-DOPA.
    Rondot P; de Recondo J; Coignet A; Ziegler M
    Adv Neurol; 1984; 40():259-69. PubMed ID: 6695602
    [No Abstract]   [Full Text] [Related]  

  • 14. [Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery].
    Matsui H; Udaka F; Oda M; Kubori T; Nishinaka K; Kameyama M
    No To Shinkei; 2004 Apr; 56(4):351-4. PubMed ID: 15237728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Case reports of some mental disorders in parkinsonian patients treated with L-dopa].
    Almici GM; Sbarbaro V
    Minerva Med; 1974 Feb; 65(8):398-401. PubMed ID: 4820722
    [No Abstract]   [Full Text] [Related]  

  • 16. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
    Pezzoli G; Martignoni E; Pacchetti C; Angeleri VA; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
    Mov Disord; 1994 Jul; 9(4):431-6. PubMed ID: 7969210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease.
    Saint-Cyr JA; Taylor AE; Lang AE
    Neurology; 1993 Dec; 43(12 Suppl 6):S47-52. PubMed ID: 8264912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
    Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Psychiatric manifestations induced by dopamine precursors or antagonists].
    Leger JM; Dumond JJ; Garoux R; Lombertie E; Dumas M
    Ann Med Psychol (Paris); 1979 Nov; 137(9):899-908. PubMed ID: 398173
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.